This week’s articles describe ways to potentially treat lymphoma and fatty liver–associated fibrosis.
CANCER
Lymphoma’s loss is a therapeutic gain
Oricchio et al. discover that loss of SESTRIN1 expression drives mTORC1 signaling in lymphoma cells and that drugs inhibiting EZH2 may be therapeutic in patients by restoring the abundance of SESTRIN.
FIBROSIS
Opposing cytokines in obesity and fibrosis
Hart et al. report that inhibiting the growth factor TGF-β and the cytokine IL-13 may suppress the development of fibrosis in patients with nonalcoholic fatty liver disease.